Skip to content
NBlaz – Lifestyle
Author:
Amneal Pharmaceuticals LLC
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson’s Disease
June 5, 2026
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
June 4, 2026
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 1, 2026
Amneal Reports First Quarter 2026 Financial Results
May 7, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 22, 2026
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
April 22, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
April 14, 2026
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
April 9, 2026
Amneal to Report First Quarter 2026 Results on May 1, 2026
April 7, 2026
1
2
Next Page
→